Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer Milin R. AcharyaJudith E. KarpAlex Sparreboom Preclinical Studies 31 March 2006 Pages: 367 - 375
The effect of single agent oral fusaric acid (FA) on the growth of subcuta neously xenografted SCC-1 cells in a nude mouse model James M. RudaKirt S. BeusBrendan C. Stack Jr. Preclinical Studies 24 February 2006 Pages: 377 - 381
The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs Ada RephaeliMichal Entin-MeerAbraham Nudelman Preclinical Studies 24 February 2006 Pages: 383 - 392
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes William C. ZamboniRamesh K. RamanathanSharon Marsh Preclinical Studies 09 March 2006 Pages: 393 - 401
A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies G. SchwartsmannL. P. DiLeoneG. De Nucci Phase I Studies 24 February 2006 Pages: 403 - 412
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies Hervé GhesquièresSandrine FaivreEric Raymond Phase I Studies 22 April 2006 Pages: 413 - 421
Phase 1 trial of Anvirzel™ in patients with refractory solid tumors Tarek MekhailHanspreet KaurRonald M. Bukowski Phase I Studies 05 April 2006 Pages: 423 - 427
Phase II study of vinflunine in patients with metastatic renal cell carcinoma D. GoldsteinS. P. AcklandM. Byrne Phase II Studies 08 March 2006 Pages: 429 - 434
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial M. KnowlingM. BlacksteinE. Eisenhauer Phase II Studies 09 March 2006 Pages: 435 - 439
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane J. A. AjaniH. SafranB. Mullaney Phase II Studies 31 March 2006 Pages: 441 - 446
Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282 Minaxi JhawerSridhar ManiDaniel Haller Phase II Studies 22 April 2006 Pages: 447 - 454
Abraxane® induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency J. Lee VillanoDivyesh MehtaLatha Radhakrishnan Case Report 24 February 2006 Pages: 455 - 456